Published in Cancer Weekly, May 5th, 2009
“Cancer research has long been a core area of focus at MedImmune and we are proud to share data from our increasingly broad oncology portfolio at this year’s meeting,” said Bahija Jallal, Ph.D., senior vice president, research.
MedImmune research scheduled to be presented includes: Identification of a human antibody 3.19.3 that inhibits ANG-2 function leading to significant anti-tumor activity in a panel of tumor xenograft...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.